Guided Therapeutics (GTHP) Payables (2010 - 2026)

Guided Therapeutics has disclosed Payables across 17 years of filings, most recently posting $2.6 million for Q2 2026.

• In Q2 2026, Payables fell 1.23% year-over-year to $2.6 million; the TTM figure through Jun 2026 stood at $2.6 million (down 1.23% YoY), while the FY2025 annual figure was $2.8 million, up 23.73% from the prior year.
• Payables came in at $2.6 million for Q2 2026 at Guided Therapeutics, up from $2.5 million in the prior quarter.
• In the past five years, Payables ranged from a high of $3.2 million in Q1 2022 to a low of $1.9 million in Q1 2024.
• Average Payables over 5 years is $2.5 million, with a median of $2.3 million recorded in 2024.
• Year-over-year, Payables gained 26.96% in 2022 and slumped 31.26% in 2023.
• Over 5 years, Payables stood at $2.2 million in 2022, then slipped by 8.6% to $2.0 million in 2023, then advanced by 8.93% to $2.2 million in 2024, then rose by 23.73% to $2.8 million in 2025, then decreased by 4.34% to $2.6 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $2.6 million in Q2 2026, $2.5 million in Q1 2026, and $2.8 million in Q4 2025.